View in EDS

The addition of celecoxib enhances the therapeutic benefit of cabozantinib and anti-PD1 in hepatocellular carcinoma.

Saved in:
Bibliographic Details
Title: The addition of celecoxib enhances the therapeutic benefit of cabozantinib and anti-PD1 in hepatocellular carcinoma.
Authors: Hsu YC; Liver Disease Prevention and Treatment Research Foundation, Taiwan; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City, Taiwan., Wu MC; Liver Disease Prevention and Treatment Research Foundation, Taiwan., Chen CH; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan; Department of Medicine, National Taiwan University Cancer Center, Taipei City, Taiwan., Lee YT; Liver Disease Prevention and Treatment Research Foundation, Taiwan., Lin CI; Liver Disease Prevention and Treatment Research Foundation, Taiwan., Chou HC; Liver Disease Prevention and Treatment Research Foundation, Taiwan., Lee HS; Liver Disease Prevention and Treatment Research Foundation, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan., Wang LF; Liver Disease Prevention and Treatment Research Foundation, Taiwan., Sheu JC; Liver Disease Prevention and Treatment Research Foundation, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan., Weng MT; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan; Department of Medical Research, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan. Electronic address: G05157@hch.gov.tw.
Source: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2026 Mar; Vol. 196, pp. 119102. Date of Electronic Publication: 2026 Feb 10.
Publication Type: Journal Article
Journal Info: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1950-6007 (Electronic) Linking ISSN: 07533322 NLM ISO Abbreviation: Biomed Pharmacother Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41655535
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The addition of celecoxib enhances the therapeutic benefit of cabozantinib and anti-PD1 in hepatocellular carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Hsu+YC%22">Hsu YC</searchLink>; Liver Disease Prevention and Treatment Research Foundation, Taiwan; Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei City, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wu+MC%22">Wu MC</searchLink>; Liver Disease Prevention and Treatment Research Foundation, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chen+CH%22">Chen CH</searchLink>; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan; Department of Medicine, National Taiwan University Cancer Center, Taipei City, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lee+YT%22">Lee YT</searchLink>; Liver Disease Prevention and Treatment Research Foundation, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lin+CI%22">Lin CI</searchLink>; Liver Disease Prevention and Treatment Research Foundation, Taiwan.<br /><searchLink fieldCode="AU" term="%22Chou+HC%22">Chou HC</searchLink>; Liver Disease Prevention and Treatment Research Foundation, Taiwan.<br /><searchLink fieldCode="AU" term="%22Lee+HS%22">Lee HS</searchLink>; Liver Disease Prevention and Treatment Research Foundation, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan.<br /><searchLink fieldCode="AU" term="%22Wang+LF%22">Wang LF</searchLink>; Liver Disease Prevention and Treatment Research Foundation, Taiwan.<br /><searchLink fieldCode="AU" term="%22Sheu+JC%22">Sheu JC</searchLink>; Liver Disease Prevention and Treatment Research Foundation, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan.<br /><searchLink fieldCode="AU" term="%22Weng+MT%22">Weng MT</searchLink>; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University, Taipei City, Taiwan; Department of Medical Research, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan. Electronic address: G05157@hch.gov.tw.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228213295%22">Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</searchLink> [Biomed Pharmacother] 2026 Mar; Vol. 196, pp. 119102. <i>Date of Electronic Publication: </i>2026 Feb 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Editions+Scientifiques+Elsevier%22">Editions Scientifiques Elsevier </searchLink><i>Country of Publication: </i>France <i>NLM ID: </i>8213295 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1950-6007 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2207533322%22">07533322 </searchLink><i>NLM ISO Abbreviation: </i>Biomed Pharmacother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41655535
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.biopha.2026.119102
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 119102
    Titles:
      – TitleFull: The addition of celecoxib enhances the therapeutic benefit of cabozantinib and anti-PD1 in hepatocellular carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Hsu YC
      – PersonEntity:
          Name:
            NameFull: Wu MC
      – PersonEntity:
          Name:
            NameFull: Chen CH
      – PersonEntity:
          Name:
            NameFull: Lee YT
      – PersonEntity:
          Name:
            NameFull: Lin CI
      – PersonEntity:
          Name:
            NameFull: Chou HC
      – PersonEntity:
          Name:
            NameFull: Lee HS
      – PersonEntity:
          Name:
            NameFull: Wang LF
      – PersonEntity:
          Name:
            NameFull: Sheu JC
      – PersonEntity:
          Name:
            NameFull: Weng MT
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2026 Mar
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1950-6007
          Numbering:
            – Type: volume
              Value: 196
          Titles:
            – TitleFull: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
              Type: main
ResultId 1